Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA: 600332) has announced that its subsidiary branch, Baiyunshan Pharmaceutical General Factory, has received the Certificate of Pharmaceutical Product Registration for Cefalexin Capsules from the Macau Special Administrative Region's Pharmaceutical Administration.

The application for the registration of Cefalexin Capsules 0.125g was submitted by Baiyunshan Pharmaceutical General Factory to the Macau authority on June 1, 2026, and received preliminary acceptance for review on June 22, 2026.

This medication is indicated for treating infections caused by susceptible bacteria, including respiratory tract infections such as acute tonsillitis, pharyngitis, otitis media, sinusitis, bronchitis, and pneumonia, as well as urinary tract infections and skin/soft tissue infections.

The product is an oral formulation and is not suitable for the treatment of severe infections.